A spate of combination approaches to kidney cancer
A combination therapy from Bristol Myers Squibb and Exelixis could help extend the lives of patients with kidney cancer compared to an older medicine, new data from ESMO show — but it’s not the only next-gen treatment option that shows this sort of efficacy.
Opdivo, the immunotherapy from BMS, and Cabometyx, a targeted cancer drug, reduced the risk of death by 40% in a Phase 3 trial as compared to Sutent, an old Pfizer drug for kidney cancer, STAT’s Adam Feuerstein writes. It also reduced the risk of disease progression by 49% compared to the older drug.
Opdivo, the immunotherapy from BMS, and Cabometyx, a targeted cancer drug, reduced the risk of death by 40% in a Phase 3 trial as compared to Sutent, an old Pfizer drug for kidney cancer, STAT’s Adam Feuerstein writes. It also reduced the risk of disease progression by 49% compared to the older drug.
.png)
No hay comentarios:
Publicar un comentario